000			03596nam a22003855i 4500
001			282791
003			MX-SnUAN
005			20160429154206.0
007			cr nn 008mamaa
008			150903s2007 ne | o |||| 0|eng d
020			_a9781402065545 _99781402065545
024	7		_a10.1007/9781402065545 _2doi
035			_avtls000335674
039		9	_a201509030754 _bVLOAD _c201404300305 _dVLOAD _y201402041306 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aKhosravi-Far, Roya. _eautor _9309794
245	1	0	_aProgrammed Cell Death in Cancer Progression and Therapy / _cby Roya Khosravi-Far, Eileen White.
264		1	_aDordrecht : _bSpringer Netherlands, _c2007.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v615
500			_aSpringer eBooks
505	0		_aCell Death: History and Future -- Caspase Mechanisms -- The Mitochondrial Death Pathway -- Apoptotic Pathways in Tumor Progression and Therapy -- Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells -- Overcoming Resistance to Apoptosis in Cancer Therapy -- Trail Receptors: Targets for Cancer Therapy -- Rational Design of Therapeutics Targeting the BCL-2 Family: Are Some Cancer Cells Primed for Death but Waiting for a Final Push? -- Autophagy and Tumor Suppression: Recent Advances in Understanding the Link between Autophagic Cell Death Pathways and Tumor Development -- Regulation of Programmed Cell Death by the P53 Pathway -- Regulation of Programmed Cell Death by NF-?B and its Role in Tumorigenesis and Therapy -- Targeting Proteasomes as Therapy in Multiple Myeloma -- Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis -- RNA Interference and Cancer: Endogenous Pathways and Therapeutic Approaches -- Cancer Stem Cells and Impaired Apoptosis.
520			_aProgrammed cell death (PCD) plays pivotal roles in tumor progression, cancer therapeutics and resistance of tumor cells to therapy. With the discovery of key mechanisms that are involved in mediating PCD and in promoting resistance to therapy, design of therapeutic approaches for promoting tumor-selective cell death has risen dramatically. With this book, we give a comprehensive overview of the mechanisms that are involved in mediating and regulating PCD in cancer. We also provide a detailed indication of the utility of PCD in cancer therapy. This book will be a valuable resource for researchers investigating the role of PCD in cancer and other diseases, researchers investigating the molecular mechanism of chemotherapeutic agents and drug-resistance in cancer and for physicians using chemotherapeutic agents. Additionally, this book will be a important educational source for PhD students specializing in cell biology, immunology and MD students interested in Oncology and Cancer Therapeutics.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aWhite, Eileen. _eautor _9309795
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781402065538
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4020-6554-5 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c282791 _d282791